EU approved the use of Avastin in platinum resistant recurrent ovarian cancer

Source: Wisdom News Agency (August 7, 2014) Roche announced on August 6, 2014 that the European Commission (EC) approved Avastin (common name: bevacizumab, bevacizumab), paclitaxel, topotecan or pegylated liposome adriamycin（ Doxorubicin) chemotherapy is used for the treatment of platinum resistant recurrent ovarian cancer in women Avastin is the first EU approved drug for platinum resistant recurrent ovarian cancer This approval gives the first new treatment option to the platinum resistant recurrent ovarian cancer patients in Europe in the past 15 years Avastin's approval was based on positive data from the stage III Aurelia study in platinum resistant recurrent ovarian cancer patients Aurelia is a multicenter, randomized, open label phase III study involving 361 patients with platinum resistant recurrent epithelial ovarian, primary peritoneal or fallopian tube cancer who have previously received no more than two anticancer therapies In the study, patients were randomly assigned to six treatment groups (paclitaxel, TECAN or liposome adriamycin, with or without Avastin) The data showed that Avastin combined chemotherapy reduced the risk of disease deterioration by 52% (PFS without progression, mean PFS: 6.7 months vs 3.4 months, P < 0.001), reaching the main end point of the study The secondary end point of total survival time (OS) showed no significant improvement (mean OS: 16.7 months vs 13.3 months, P < 0.174) The Aurelia study is the fourth phase III study to confirm that Avastin combined chemotherapy can significantly improve the progression free survival (PFS) of ovarian cancer In Europe, the European Union approved Avastin for the first-line treatment of advanced ovarian cancer (based on the key phase III Gog 0128 and icon7 study) in 2011 and for the treatment of recurrent platinum sensitive ovarian cancer (based on the key phase III oceans study) in 2012 Of all gynecological cancers, ovarian cancer has the highest mortality rate In the European Union, 44000 new cases of ovarian cancer are added every year, many of which may have reached the advanced stage and relapse after initial treatment In the treatment of recurrent ovarian cancer, the time between the last platinum containing chemotherapy and the recurrence of the disease was used to help determine the chemotherapy options in the next line of treatment If the patient's condition worsens within 1-6 months after the completion of platinum containing chemotherapy, it is called platinum resistant ovarian cancer; if the condition worsens after 6 months, it is called platinum sensitive ovarian cancer In the European Union, one quarter (more than 10000 cases) of ovarian cancer patients who relapse after initial treatment are platinum resistant ovarian cancer every year, which is the most difficult type of ovarian cancer to treat.